2026 Dyslipidemia Guideline Expands Statin Eligibility

Key Takeaways

• A JAMA statin-eligibility analysis estimated that 87.5 million statin-eligible nonpregnant U.S. adults ages 30-79, including 21.5 million newly eligible, would meet 2026 dyslipidemia guideline criteria; the added candidates were described as younger and lower risk.
• A JAMA PREVENT reclassification analysis projected that adopting PREVENT would reclassify over one in five adults, with about two-thirds shifting to lower-risk categories and one-third to higher-risk categories, while the proportion of adults ages 40-79 who may be recommended lipid-lowering therapy remained nearly unchanged at 49.6% versus 49.4%.
• A JAMA LDL-C goal analysis found that the estimated proportion of primary-prevention adults above LDL-C goal increased with higher PREVENT-estimated cardiovascular risk, rising from 9.9% in low-risk adults to 63.6% in borderline/intermediate-risk adults and 82.7% in high-risk adults.

The updated dyslipidemia framework appears to shift statin eligibility toward younger, lower-risk adults. Three separate JAMA analyses used NHANES data to examine how the updated dyslipidemia guideline may reshape population-level risk classification, treatment eligibility, and LDL-C goal attainment. The eligibility estimate came from NHANES 2017-2023, the reclassification and older-candidate comparison used NHANES 1999-2020, and the LDL-C goal analysis used NHANES 2021-2023. In primary prevention, PREVENT was the reported risk framework, with lipid-lowering therapy able to be considered at 10-year risk 3% to less than 5% and should be considered at 5% to less than 10%.

In nationally representative estimates from NHANES 2017-2023, investigators found that 21.5 million nonpregnant U.S. adults ages 30-79 would become newly statin eligible under the 2026 guideline, contributing to 87.5 million adults eligible overall in the JAMA statin-eligibility analysis. The newly eligible group was described as younger and lower risk, with mean 10-year ASCVD risk of 3.1% versus 6.1% in populations previously recommended statin therapy.

In the JAMA PREVENT reclassification analysis, investigators projected that PREVENT-based adoption would move over one in five adults into different risk categories, with about two-thirds reassigned downward and one-third upward. Downward reclassification was reported more often among men, Black individuals, and current smokers, whereas upward reclassification was more common among women and people with diabetes. In a separate comparison limited to adults ages 40-79, the overall pool who may be recommended lipid-lowering therapy changed little under the updated guideline, at 49.6% versus 49.4%.

LDL-C goal attainment showed a different pattern, with treatment gaps concentrated in groups with higher estimated cardiovascular risk. Among primary-prevention adults ages 30-79, the estimated proportion above LDL-C goal rose from 9.9% in low-risk adults to 63.6% in borderline/intermediate-risk adults and 82.7% in high-risk adults in the JAMA LDL-C goal analysis. These were NHANES-based projections rather than observed post-guideline prescribing changes, and the reported gradient increased steadily across risk strata.

Clinician Questions

How many U.S. adults would become newly statin eligible under the 2026 dyslipidemia guideline?

An Anderson-led JAMA estimate found that 21.5 million nonpregnant U.S. adults ages 30-79, or 13.9%, were newly statin eligible under the 2026 guideline, while 87.5 million adults, or 56.6%, were statin eligible overall.

How did cardiovascular risk differ between newly statin-eligible adults and previously recommended populations in the 2026 guideline analysis?

Newly statin-eligible adults were described as younger and lower risk, with mean estimated 10-year ASCVD risk of 3.1% versus 6.1% in populations previously recommended statin therapy.

How does PREVENT change statin risk classification under the 2026 cholesterol guideline?

A JAMA NHANES analysis projected reclassification of over one in five adults under PREVENT, with about two-thirds reassigned to lower-risk categories and one-third to higher-risk categories; downward shifts were more common among men, Black individuals, and current smokers, while upward shifts were more common among women and people with diabetes.

What LDL-C goal gaps were reported across PREVENT risk groups in primary prevention adults?

An Abohashem-led JAMA analysis in adults ages 30-79 found that the estimated proportion above LDL-C goal was 9.9% in PREVENT-estimated low-risk adults, 63.6% in borderline/intermediate-risk adults, and 82.7% in high-risk adults, describing a risk-stratified gradient in goal attainment.